268 related articles for article (PubMed ID: 38041865)
1. Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document.
Vanderniet JA; Szymczuk V; Högler W; Beck-Nielsen SS; Uday S; Merchant N; Crane JL; Ward LM; Boyce AM; Munns CF
J Clin Endocrinol Metab; 2024 Apr; 109(5):1371-1382. PubMed ID: 38041865
[TBL] [Abstract][Full Text] [Related]
2. Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report.
Del Sindaco G; Berlanga P; Brugières L; Thebault E; Mantovani G; Wicart P; Linglart A
Front Endocrinol (Lausanne); 2021; 12():698963. PubMed ID: 34335473
[TBL] [Abstract][Full Text] [Related]
3. Denosumab: an Emerging Therapy in Pediatric Bone Disorders.
Boyce AM
Curr Osteoporos Rep; 2017 Aug; 15(4):283-292. PubMed ID: 28643220
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
5. Denosumab Treatment for Giant Cell Tumors, Aneurysmal Bone Cysts, and Fibrous Dysplasia-Risks and Benefits.
Pan KS; Boyce AM
Curr Osteoporos Rep; 2021 Apr; 19(2):141-150. PubMed ID: 33616817
[TBL] [Abstract][Full Text] [Related]
6. Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty-results from a randomized placebo-controlled clinical trial.
Sköld C; Kultima K; Freyhult E; Larsson A; Gordh T; Hailer NP; Mallmin H
Osteoporos Int; 2022 Sep; 33(9):1-8. PubMed ID: 35608639
[TBL] [Abstract][Full Text] [Related]
7. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
8. Is denosumab associated with an increased risk for infection in patients with low bone mineral density? A systematic review and meta-analysis of randomized controlled trials.
Catton B; Surangiwala S; Towheed T
Int J Rheum Dis; 2021 Jul; 24(7):869-879. PubMed ID: 33793076
[TBL] [Abstract][Full Text] [Related]
9. Chondroblastoma Expresses RANKL by RNA In Situ Hybridization and May Respond to Denosumab Therapy.
Suster DI; Kurzawa P; Neyaz A; Jarzembowski JA; Lozano-Calderon S; Raskin K; Schwab J; Choy E; Chebib I; Deshpande V
Am J Surg Pathol; 2020 Dec; 44(12):1581-1590. PubMed ID: 32826531
[TBL] [Abstract][Full Text] [Related]
10. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
Sørensen AL; Hansen RL; Jørgensen PH
Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
[TBL] [Abstract][Full Text] [Related]
11. Preoperative Denosumab plus Surgery in the Management of Giant Cell Tumor of Bone: A Comprehensive Narrative Literature Review.
Abu-Zaid A; Alaqaili SI; Ahmad SO; Bin Hazzaa I; Alharbi H
Gulf J Oncolog; 2019 May; 1(30):67-75. PubMed ID: 31242985
[TBL] [Abstract][Full Text] [Related]
12. A case of minimal change disease after the administration of anti receptor activator of nuclear factor kappa B ligand (RANKL) monoclonal antibody: a case report.
Horikoshi K; Sakai N; Yamamoto N; Ogura H; Sato K; Miyagawa T; Kitajima S; Toyama T; Hara A; Iwata Y; Shimizu M; Furuichi K; Wada T
BMC Nephrol; 2020 Sep; 21(1):416. PubMed ID: 32993539
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of Osteosclerotic Change Following Treatment with an Antibody Against RANKL for Giant Cell Tumour of the Bone.
Rosario M; Takeuchi A; Yamamoto N; Hayashi K; Miwa S; Higuchi T; Abe K; Taniguchi Y; Aiba H; Tanzawa Y; Murakami H; Tsuchiya H
Anticancer Res; 2017 Feb; 37(2):749-754. PubMed ID: 28179326
[TBL] [Abstract][Full Text] [Related]
14. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
15. Severe hypercalcemia following denosumab treatment in a juvenile patient.
Setsu N; Kobayashi E; Asano N; Yasui N; Kawamoto H; Kawai A; Horiuchi K
J Bone Miner Metab; 2016 Jan; 34(1):118-22. PubMed ID: 26056018
[TBL] [Abstract][Full Text] [Related]
16. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
17. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system.
Tanaka Y; Ohira T
Curr Opin Pharmacol; 2018 Jun; 40():110-119. PubMed ID: 29702364
[TBL] [Abstract][Full Text] [Related]
19. Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review.
Wang D; Tang X; Shi Q; Wang R; Ji T; Tang X; Guo W
Transl Pediatr; 2023 Mar; 12(3):470-486. PubMed ID: 37035391
[TBL] [Abstract][Full Text] [Related]
20. Surgical Management and Denosumab for Aneurysmal Bone Cysts of the Spine in an Australian Tertiary Paediatric Centre.
Vanderniet JA; Tsinas D; Wall CL; Girgis CM; London K; Keane C; Briody J; Hibbert S; Poon M; Padhye B; Biggin A; Dalla-Pozza L; Gray RJ; Munns CF
Calcif Tissue Int; 2023 May; 112(5):592-602. PubMed ID: 36810677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
